Loading
A Japanese study gave radiotherapy to the nose at the same time as a reduced-dose chemotherapy regimen, and three out of four people with early nasal NK/T-cell lymphoma were alive two years later, against fewer than half with radiotherapy alone in the past.
A phase 1/2 study of concurrent chemoradiotherapy in newly diagnosed stage IE or contiguous IIE nasal natural killer/T-cell lymphoma with cervical node involvement and performance status 0 to 2. Treatment was radiotherapy to 50 Gy given at the same time as three courses of DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin), drugs chosen because they are not affected by the multidrug-resistance pump the tumour expresses. The phase 1 part set the recommended dose at two thirds of full DeVIC. No ClinicalTrials.gov record was found for the study when the registry was searched on 3 November 2026, so it is a paper here and not a trial record.
The study that established concurrent chemoradiotherapy, rather than radiotherapy alone, for localised nasal NK/T-cell lymphoma in Japan. The entity page's statement that early disease is treated with radiotherapy at about 50 Gy combined with chemotherapy rests on this design; later Chinese and Korean regimens kept the radiotherapy and changed the chemotherapy.
Shares Extranodal NK/T-cell lymphoma, Ifosfamide, Dexamethasone, Etoposide and the tag lymphoma-evidence-entities.
Shares Extranodal NK/T-cell lymphoma, Ifosfamide, Dexamethasone, Etoposide and the tag lymphoma-evidence-entities.
Shares Extranodal NK/T-cell lymphoma, Dexamethasone and the tag lymphoma-evidence-entities.
Shares Extranodal NK/T-cell lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag lymphoma-evidence-entities.
Shares Etoposide, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Carboplatin, Cytotoxic chemotherapy and the tag lymphoma-evidence-entities.
Shares Extranodal NK/T-cell lymphoma and the tag lymphoma-evidence-entities.
Shares Etoposide, Cytotoxic chemotherapy and the tag lymphoma-evidence-entities.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag lymphoma-evidence-entities.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/